Asthma is treated with a combination of medicines, trigger management, monitoring, education and an individualised action plan. The central aim is to control airway inflammation, prevent symptoms and exacerbations, maintain normal activity and reduce the risk of severe attacks. Treatment depends on age, symptom frequency, severity, lung-function findings, previous attacks, response to medicines, inhaler technique, adherence, smoking or occupational exposure, allergies and other medical conditions. Asthma is not currently curable, but appropriate treatment can provide very good long-term control.
Inhaled medicines are particularly important because they deliver active drugs directly to the airways, allowing effective treatment with substantially less systemic exposure than many oral medicines. Modern asthma management therefore focuses not simply on relieving breathlessness when it occurs, but on controlling the underlying inflammatory disease that makes the airways abnormally reactive.
The principal medicines are inhaled corticosteroids, bronchodilators and, when necessary, additional controller medicines. Inhaled corticosteroids, commonly abbreviated ICS, reduce inflammation and swelling inside the airways and decrease airway hyper-responsiveness. Examples include budesonide, beclometasone and fluticasone. Bronchodilators relax airway smooth muscle and widen narrowed airways. Some modern inhalers combine an ICS with formoterol, a long-acting bronchodilator.
Depending on the treatment pathway, an anti-inflammatory reliever inhaler can be used when symptoms occur, or the same combination inhaler can be used both regularly and as needed in maintenance-and-reliever therapy, usually abbreviated MART. NICE and BTS/SIGN guidance uses ICS-containing treatment as a fundamental component of pharmacological management rather than relying on a short-acting bronchodilator alone.
Treatment is adjusted according to how well asthma is controlled. A person with infrequent symptoms may receive an anti-inflammatory reliever approach, whereas someone requiring more consistent control may use a daily maintenance inhaler or MART regimen. If symptoms remain inadequately controlled, clinicians first investigate practical explanations such as incorrect inhaler technique, missed doses, continued exposure to triggers, smoking, occupational exposures, an incorrect diagnosis or another untreated condition.
Treatment can then be stepped up by changing the inhaler regimen or adding another medicine. Conversely, when asthma remains well controlled for an appropriate period, treatment may sometimes be stepped down cautiously to the lowest effective regimen. This stepwise approach is important because asthma severity and asthma control are not identical concepts: a person may have relatively mild underlying disease but temporarily poor control, while someone requiring substantial treatment may have severe asthma despite good current control.
Reliever treatment is designed to provide rapid improvement when airway narrowing causes acute symptoms, but relying excessively on reliever medication can indicate inadequate control of the underlying inflammation. Traditional short-acting beta2 agonists, or SABAs, rapidly relax airway smooth muscle, while formoterol has a sufficiently rapid onset to be incorporated into certain anti-inflammatory reliever and MART strategies. The precise inhaler and maximum permitted doses depend on the prescribed regimen and the person's action plan.
During an asthma attack, sitting upright and following the personalised action plan are important. NHS guidance states that emergency help is required when symptoms worsen, when the maximum prescribed reliever dose does not provide adequate improvement, or when an inhaler is unavailable. Severe attacks may require hospital treatment including oxygen, nebulised medicines and systemic corticosteroids.
Inhaler technique is a major component of treatment because a correctly prescribed medicine cannot work effectively if insufficient drug reaches the lungs. Different devices have different requirements: pressurised metered-dose inhalers require coordinated actuation and inhalation, dry-powder inhalers require an appropriate inhalation manoeuvre, and soft-mist inhalers produce a slower aerosol. Spacers can improve delivery from appropriate pressurised inhalers and reduce deposition in the mouth and throat.
Patients should have their technique checked periodically by a healthcare professional rather than assuming that familiarity means correct technique. Preventer inhalers must generally be used consistently even when symptoms have disappeared because their purpose is to suppress the inflammatory tendency that produces future symptoms. Corticosteroid inhalers can cause local effects such as oral thrush and hoarseness, with mouth rinsing after use helping to reduce these problems.
If inhaled treatment does not adequately control asthma, additional medicines can be considered. Leukotriene receptor antagonists such as montelukast can be useful for selected patients, including some people with exercise-related or allergic components, although their risks and benefits need individual assessment. Long-acting muscarinic antagonists and other add-on therapies may be considered in more difficult cases. Some people with severe asthma have particular inflammatory phenotypes involving pathways such as IgE, interleukin-5 or interleukin-4/interleukin-13.
Specialist services can assess whether biologic medicines are appropriate for these patients. Biological therapies are targeted treatments administered by injection or infusion and can substantially reduce exacerbations in appropriately selected people with severe disease. They are not routine substitutes for inhaled corticosteroids and are generally considered after specialist assessment and confirmation that conventional treatment has been optimised.
Non-drug management complements medication. Patients are generally advised to identify and reduce avoidable triggers such as tobacco smoke, occupational sensitising agents, relevant allergens, air pollution and particular environmental exposures. Exercise is normally encouraged because well-controlled asthma should not prevent ordinary physical activity, although exercise can provoke bronchoconstriction in some people and may require preventive treatment. Vaccination, management of allergic disease and attention to weight, reflux or rhinitis may also be relevant where these factors affect control.
Written asthma action plans explain the person's regular medicines, how to recognise deterioration, what additional treatment to take and when to seek emergency help. Regular reviews assess symptoms, exacerbation history, inhaler technique, adherence, lung function where appropriate and whether treatment should be changed. NHS guidance recommends at least annual asthma reviews, with additional assessment when control is poor or treatment changes.
Severe asthma attacks can be life-threatening because extreme airway narrowing, mucus production and inflammation can severely restrict ventilation. Emergency management may require repeated inhaled bronchodilator treatment, oxygen, systemic corticosteroids and, in severe cases, additional hospital interventions. A person who has recovered from an attack still requires prompt medical review because an exacerbation indicates increased future risk and may reveal that the maintenance regimen needs modification.
Asthma treatment therefore operates at several levels: long-term anti-inflammatory control, rapid relief of acute bronchoconstriction, prevention of exacerbations, identification of triggers, monitoring and emergency planning. The appropriate treatment is not determined solely by how breathless someone feels on a particular day; clinicians integrate symptom patterns, objective testing, treatment response and exacerbation history. Properly implemented, this approach can allow many people with asthma to live normally with minimal symptoms while reducing preventable severe attacks.
